Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

cetuximab

  • Open Access
    Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial
    MARK T.J. VAN BUSSEL, NATHALIE BRAVENBOER, HUIB VAN ESSEN, PETUR SNAEBJORNSSON, NATASHA M. APPELMAN-DIJKSTRA, JAN HM SCHELLENS and FRANS L. OPDAM
    Anticancer Research July 2025, 45 (7) 3137-3147; DOI: https://doi.org/10.21873/anticanres.17677
  • Open Access
    Antibody-dye Conjugates Targeting EGFR and HER2 for the Photoimmunotherapy of Bladder Cancer
    FABIAN HUBER, ISIS WOLF, JONAS STORZ, SUSANNE SCHULTZE-SEEMANN, SUSAN LAUW, LUKAS KLEMENZ, ARKADIUSZ MIERNIK, CHRISTIAN GRATZKE, REINHARD BRÜCKNER and PHILIPP WOLF
    Anticancer Research May 2024, 44 (5) 1837-1844; DOI: https://doi.org/10.21873/anticanres.16985
  • You have access
    Comparative Effectiveness of Cetuximab Versus Panitumumab in Patients With Metastatic Colorectal Cancer: A Nationwide Database Study
    CHIH-CHIEN WU, CHIEN-CHOU SU, YU-HSUN CHEN, CHAO-WEN HSU, MENG-CHE HSIEH, YU-CHING CHANG, YUNG-CHANG WANG and YI-CHIA SU
    Anticancer Research November 2023, 43 (11) 5127-5138; DOI: https://doi.org/10.21873/anticanres.16713
  • You have access
    CDX2-positive Cancer of Unknown Primary With Upper-body Paralysis Was Dramatically Improved by Colorectal Cancer Chemotherapy
    HIDEKO AKAGI, YUSAKU TANAKA, KOHEI WADA, MIANAMI TAKAHASHI, KOUDAI YOSHIDA and HIDEHARU DOMOTO
    Anticancer Research June 2023, 43 (6) 2879-2884; DOI: https://doi.org/10.21873/anticanres.16458
  • You have access
    Real-world Data Study of the Efficacy and Toxicity of Nivolumab vs. Cetuximab and Predictors of Response to Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck in a European Population
    LOLA MACIA-RIVAS, CLARA LUZ FERNANDEZ-LAGUNA, CRISTINA ALVAREZ-ASTEINZA, IVAN MARAY, MONICA CARBAJALES-ALVAREZ and ANA LOZANO-BLAZQUEZ
    Anticancer Research April 2023, 43 (4) 1681-1688; DOI: https://doi.org/10.21873/anticanres.16320
  • You have access
    Study of the Acquisition of Sensitivity to Paclitaxel Plus Cetuximab by the Addition of Low-dose Proteasome Inhibitor
    MASAKI YODA, KANAME SAKUMA, TOMOYUKI KII and AKIRA TANAKA
    Anticancer Research September 2022, 42 (9) 4273-4283; DOI: https://doi.org/10.21873/anticanres.15927
  • You have access
    Effectiveness of Hyperthermia as Monotherapy and Adjuvant Therapy Approaches Against an In Vitro Model of Colorectal Carcinoma
    GEORGIOS PETRAKIS, THEODORA MANTSO, MICHAIL I. KOUKOURAKIS, MIHALIS I. PANAYIOTIDIS and SOTIRIS BOTAITIS
    Anticancer Research May 2022, 42 (5) 2363-2374; DOI: https://doi.org/10.21873/anticanres.15715
  • You have access
    Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen
    HIROAKI TANIOKA, KEN SHIMADA, AKIHITO TSUJI, MITSUGU KOCHI, HO MIN KIM, TAKAO TAKAHASHI, TADAMICHI DENDA, AKINORI TAKAGANE, TAKANORI WATANABE, MASAHITO KOTAKA, MASATO NAKAMURA, YU SUNAKAWA, MASAHIRO TAKEUCHI, WATARU ICHIKAWA and MASASHI FUJII
    Anticancer Research May 2022, 42 (5) 2675-2681; DOI: https://doi.org/10.21873/anticanres.15745
  • You have access
    Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma
    TOMOFUMI NARUSE, SOUICHI YANAMOTO, MITSUNOBU OTSURU, NOBUHIRO YAMAKAWA, TADAAKI KIRITA, YUKARI SHINTANI, TATSUSHI MATSUMURA, MASAYA OKURA, MASASHI SASAKI, YOSHIHIDE OTA, SHIN-ICHI YAMADA, HIROSHI KURITA, MASAHIRO UMEDA and JAPAN ORAL ONCOLOGY GROUP (JOOG)
    Anticancer Research November 2021, 41 (11) 5785-5791; DOI: https://doi.org/10.21873/anticanres.15395
  • You have access
    PTEN Is Activated by the Addition of Cetuximab to Paclitaxel in Oral Squamous Cell Carcinoma
    TOMOYUKI KII, KANAME SAKUMA and AKIRA TANAKA
    Anticancer Research July 2021, 41 (7) 3363-3370; DOI: https://doi.org/10.21873/anticanres.15124

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire